Since 1976, Tufts CSDD has provided robust, objective evidence-based research, analysis, and insight, which have informed stakeholders throughout the drug development enterprise. Here are select Tufts CSDD research milestones during our 46+ year history:
![](https://csdd.tufts.edu/hubfs/TuftsCSDD_June2021/images/Drug+lag.png)
![cost to develop new drug](https://csdd.tufts.edu/hubfs/TuftsCSDD_June2021/images/cost+to+develop+new+drug.png)
![patent life therapeutic compounds](https://csdd.tufts.edu/hubfs/TuftsCSDD_June2021/images/patent+life+therapeutic+compounds.png)
![orphan drug act](https://csdd.tufts.edu/hubfs/TuftsCSDD_June2021/images/orphan+drug+act.png)
![drug safety withdrawals](https://csdd.tufts.edu/hubfs/TuftsCSDD_June2021/images/drug+safety+withdrawals.png)
![fda post-approval research](https://csdd.tufts.edu/hubfs/TuftsCSDD_June2021/images/fda+post-approval+research.png)
![new drug cost study](https://csdd.tufts.edu/hubfs/TuftsCSDD_June2021/images/new+drug+cost+study.png)
![biotechnology product discovery international](https://csdd.tufts.edu/hubfs/TuftsCSDD_June2021/images/biotechnology+product+discovery+international.png)
![biotechnology success rates](https://csdd.tufts.edu/hubfs/TuftsCSDD_June2021/images/biotechnology+success+rates.png)
![FDAMA](https://csdd.tufts.edu/hubfs/TuftsCSDD_June2021/images/FDAMA.png)
![FDA sponsor meetings new drug](https://csdd.tufts.edu/hubfs/TuftsCSDD_June2021/images/FDA+sponsor+meetings+new+drug.png)
![PDUFA drug development times](https://csdd.tufts.edu/hubfs/TuftsCSDD_June2021/images/PDUFA+drug+development+times.png)
![FDAMA pediatric research incentive program](https://csdd.tufts.edu/hubfs/TuftsCSDD_June2021/images/FDAMA+pediatric+research+incentive+program.png)
![new drug biopharmaceutical approval times centralized procedure european medicines evaluation agency](https://csdd.tufts.edu/hubfs/TuftsCSDD_June2021/images/new+drug+biopharmaceutical+approval+times+centralized+procedure+european+medicines+evaluation+agency.png)
![cost pharmaceutical r&d develop new drug](https://csdd.tufts.edu/hubfs/TuftsCSDD_June2021/images/cost+pharmaceutical+r%26d+develop+new+drug.png)
![FDA fast track program development times](https://csdd.tufts.edu/hubfs/TuftsCSDD_June2021/images/FDA+fast+track+program+development+times.png)
![follow-on drug development incremental innovation](https://csdd.tufts.edu/hubfs/TuftsCSDD_June2021/images/follow-on+drug+development+incremental+innovation.png)
![drug safety withdrawals speed regulatory approval lack of correlation](https://csdd.tufts.edu/hubfs/TuftsCSDD_June2021/images/drug+safety+withdrawals+speed+regulatory+approval+lack+of+correlation.png)
![cost develop new biotechnology product](https://csdd.tufts.edu/hubfs/TuftsCSDD_June2021/images/cost+develop+new+biotechnology+product+$1.png)
![outsourcing practice individual outsourcing models](https://csdd.tufts.edu/hubfs/TuftsCSDD_June2021/images/outsourcing+practice+individual+outsourcing+models.png)
![oncology drug R&D approval success rate 8%](https://csdd.tufts.edu/hubfs/TuftsCSDD_June2021/images/oncology+drug+R%26D+approval+success+rate+8%25.png)
![US drug plans 88% therapeutic non-compliant medicare regulations](https://csdd.tufts.edu/hubfs/TuftsCSDD_June2021/images/US+drug+plans+88%25+therapeutic+non-compliant+medicare+regulations.png)
![new drug clinical success rates clinical success rates 16%](https://csdd.tufts.edu/hubfs/TuftsCSDD_June2021/images/new+drug+clinical+success+rates+clinical+success+rates+16%25.png)
![orphan drug development 25% new approvals](https://csdd.tufts.edu/hubfs/TuftsCSDD_June2021/images/orphan+drug+development+25%25+new+approvals.png)
![clinical useful diagnostics personalized medicines incidence protocol](https://csdd.tufts.edu/hubfs/TuftsCSDD_June2021/images/clinical+useful+diagnostics+personalized+medicines+incidence+protocol.png)
![protocol complexity](https://csdd.tufts.edu/hubfs/TuftsCSDD_June2021/images/protocol+complexity.png)
![vaccine development trends](https://csdd.tufts.edu/hubfs/TuftsCSDD_June2021/images/vaccine+development+trends.png)
![average cost pharmaceutical R&D](https://csdd.tufts.edu/hubfs/TuftsCSDD_June2021/images/average+cost+pharmaceutical+R%26D.png)
![rapid growth pharmaceutical benefit managers exclusion lists drug developers](https://csdd.tufts.edu/hubfs/TuftsCSDD_June2021/images/rapid+growth+pharmaceutical+benefit+managers+exclusion+lists+drug+developers.png)
![FDA 505 (b) (2) regulatory pathway review+process+molecular entity approvals](https://csdd.tufts.edu/hubfs/TuftsCSDD_June2021/images/FDA+505+(b)+(2)+regulatory+pathway+review+process+molecular+entity+approvals.png)
![data volume data diversity clinical trials](https://csdd.tufts.edu/hubfs/TuftsCSDD_June2021/images/data+volume+data+diversity+clinical+trials.png)
![patient engagement oncology development programs](https://csdd.tufts.edu/hubfs/TuftsCSDD_June2021/images/patient+engagement+oncology+development+programs.png)
![real world evidence data artificial intelligence](https://csdd.tufts.edu/hubfs/TuftsCSDD_June2021/images/real+world+evidence+data+artificial+intelligence.png)
![volume cost vendor qualification re-qualification](https://csdd.tufts.edu/hubfs/TuftsCSDD_June2021/images/volume+cost+vendor+qualification+re-qualification.png)
![participant demographic diversityp ivotal+trials+FDA+approved+drugs+biologics](https://csdd.tufts.edu/hubfs/TuftsCSDD_June2021/images/participant+demographic+diversity+pivotal+trials+FDA+approved+drugs+biologics.png)
![Conducts first empirical study on the diversity of global site personnel and finds a strong positive correlation between the race and ethnicity of study staff and patients enrolled](https://csdd.tufts.edu/hubfs/Timeline_Cycle%20(2).png)
![Derives first cycle time benchmarks on the stages of adopting innovations supporting clinical operations](https://csdd.tufts.edu/hubfs/Timeline_Cycle.png)